Search

Search Results

• Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

  L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya, A.G. Turkina

  104-111

  01.01.2020

• Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)

  Ekaterina Yur’evna Chelysheva, A.G. Turkina, E.S. Polushkina, M.A. Vinogradova, R.G. Shmakov

  202-210

  01.04.2019

• Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)

  Vera Vyacheslavovna Tikhonova, M.A. Isakov, V.A. Misyurin, Yu.P. Finashutina, L.A. Kesaeva, N.A. Lyzhko, I.N. Soldatova, N.N. Kasatkina, E.N. Misyurina, A.V. Misyurin

  227-233

  01.07.2018

• Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice

  Anna Grigor’evna Turkina, N.V. Novitskaya, A.K. Golenkov, V.A. Shuvaev, L.I. Napso, I.V. Krylova, A.M. Savrilova, G.Sh. Safuanova, A.V. Korobkin, T.Yu. Klitochenko, E.V. Burnasheva, E.V. Vasil’ev, O.M. Senderova, E.Yu. Fedorova, L.M. Yalunina, E.K. Nekhai, G.B. Kuchma, A.S. Lyamkina, N.G. Shchedrova

  390-401

  01.07.2017

• Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

  Tat’yana Ivanovna Ionova, N.B. Bulieva, O.Yu. Vinogradova, T.A. Gritsenko, L.K. Kozlova, G.B. Kuchma, E.G. Lomaia, E.R. Machyulaitene, T.P. Nikitina, N.V. Novitskaya, A.Yu. Rodionova, E.I. Usacheva, T.V. Shneider

  206-217

  01.04.2017

• Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors

  Galina Anatol’evna Gusarova, A.G. Turkina

  474-484

  01.10.2016

• Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy

  K.M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I.S. Martynkevich, M.S. Fominykh, N.A. Potikhonova, I.I. Zotova, V.Yu. Udal’eva, R.A. Golovchenko, N.V. Shakhvorostova, D.I. Shikhbabaeva, M.N. Zenina, S.A. Tiranova, S.A. Kudryashova, L.S. Martynenko, M.P. Ivanova, N.Yu. Tsybakova, E.V. Petrova, L.B. Polushkina, E.V. Kleina

  54-60

  01.01.2016

• First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors

  Vasilii Anatol’evich Shuvaev, K.M. Abdulkadyrov, I.S. Martynkevich, M.S. Fominykh

  78–83

  01.01.2015

• Current best options for first line treatment of chronic phase chronic myeloid leukemia

  R. Hehlmann, S. Saußele

  9-15

  01.01.2014

• Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia

  A.A. Zeifman, E.Yu. Chelysheva, A.G. Tukrina, G.G. Chilov

  16-27

  01.01.2014

• Quality of life and symptom profile in patients with chronic myeloid leukemia receiving dasatinib as а second-line therapy due to intolerance or resistance to imatinib

  T.I. Ionova, D.A. Fedorenko, T.P. Nikitina, K.A. Kurbatova

  166-176

  01.04.2013

• Cardiovascular complications of chronic myeloid leukemia treated with tyrosine kinase inhibitors

  G.E. Gendlin, L.M. Makeeva, E.I. Emelina, K.V. Shuikova, G.I. Storozhakov

  78-84

  01.01.2013